Shareholders in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance. The market may be pricing in some blue sky too, with the share price gaining 10% to US$32.78 in the last 7 days. Could this upgrade be enough to drive the stock even higher?

Our free stock report includes 1 warning sign investors should be aware of before investing in Ionis Pharmaceuticals. Read for free now.

Following the upgrade, the most recent consensus for Ionis Pharmaceuticals from its 23 analysts is for revenues of US$748m in 2025 which, if met, would be a modest 4.3% increase on its sales over the past 12 months. Losses are expected to increase slightly, to US$3.02 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$656m and losses of US$3.83 per share in 2025. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

Check out our latest analysis for Ionis Pharmaceuticals NasdaqGS:IONS Earnings and Revenue Growth May 5th 2025

Despite these upgrades, the analysts have not made any major changes to their price target of US$57.31, implying that their latest estimates don't have a long term impact on what they think the stock is worth.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that Ionis Pharmaceuticals is forecast to grow faster in the future than it has in the past, with revenues expected to display 5.8% annualised growth until the end of 2025. If achieved, this would be a much better result than the 3.8% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 18% per year. Although Ionis Pharmaceuticals' revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Ionis Pharmaceuticals' prospects. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to this year's earnings expectations, it might be time to take another look at Ionis Pharmaceuticals.

Story Continues

Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Ionis Pharmaceuticals going out to 2027, and you can see them free on our platform here..

Of course, seeing company management  invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments